Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2018 3
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Dehdashti F, et al. Among authors: diebolder p. Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13. Breast Cancer Res Treat. 2018. PMID: 29442264 Free PMC article.
Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution.
Diebolder P, Vazquez-Pufleau M, Bandara N, Mpoy C, Raliya R, Thimsen E, Biswas P, Rogers BE. Diebolder P, et al. Int J Nanomedicine. 2018 Nov 12;13:7375-7393. doi: 10.2147/IJN.S177350. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30519021 Free PMC article.
Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.
Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Bandara N, et al. Among authors: diebolder pj. Nucl Med Biol. 2018 Jul-Aug;62-63:71-77. doi: 10.1016/j.nucmedbio.2018.06.001. Epub 2018 Jun 8. Nucl Med Biol. 2018. PMID: 29929115 Free PMC article.
Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential.
Diebolder P, Keller A, Haase S, Schlegelmilch A, Kiefer JD, Karimi T, Weber T, Moldenhauer G, Kehm R, Eis-Hübinger AM, Jäger D, Federspil PA, Herold-Mende C, Dyckhoff G, Kontermann RE, Arndt MA, Krauss J. Diebolder P, et al. MAbs. 2014 Jan-Feb;6(1):130-42. doi: 10.4161/mabs.27236. MAbs. 2014. PMID: 24256717 Free PMC article. Clinical Trial.
Translation of ceragenin affinity for bacteria to an imaging reagent for infection.
Bandara N, Li Y, Diebolder P, Mpoy C, Gu X, Khanal P, Deng S, Rogers BE, Savage PB. Bandara N, et al. Among authors: diebolder p. RSC Adv. 2019;9(25):14472-14476. doi: 10.1039/c9ra02226k. Epub 2019 May 8. RSC Adv. 2019. PMID: 32864109 Free PMC article.
Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D. Hornig N, et al. Among authors: diebolder p. J Immunother. 2012 Jun;35(5):418-29. doi: 10.1097/CJI.0b013e3182594387. J Immunother. 2012. PMID: 22576347
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
Diebolder P, Mpoy C, Scott J, Huynh TT, Fields R, Spitzer D, Bandara N, Rogers BE. Diebolder P, et al. J Nucl Med. 2020 Jun 8:jnumed.120.249557. doi: 10.2967/jnumed.120.249557. Online ahead of print. J Nucl Med. 2020. PMID: 32513906
Feedback